Galmed unveils novel pharmacodynamic blood markers for aramchol, the most clinically advanced scd1 inhibitor

Analysis of blood samples from patients treated with aramchol in armor (ph3 mash study) provides new and important insights into the biochemical and physiological effects of the drug. the pharmacodynamic signature associated with aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.
GLMD Ratings Summary
GLMD Quant Ranking